Shorts - general info, page-178

This should be $33 plus, not $30. Neither is $45 plus out of the question. Management are failing in properly giving analysts the ability to rate CUV where it should be. It is time for management to give greater understanding of the underlying capability of afamelanotide in its various forms and its extensive capability in dealing with a multitude of diseases - irrespective of whether there might be competition in dealing with those diseases. CUV should now be giving a much greater flavour of where the peptide has capability of delivering. It is not the time to be coy. It is time to lay down the various paths CUV management know the peptide can go. Heavens knows, they have huge info on this and so much underlying physical use information. DNA repair is not as easily understood in terms of the real capability but diseases like MS are and other autoimmune diseases. For heavens sake, get the 10 year program out there. Get people understanding at a basic level at least of the ambition. FDA has happened. In the bag. Get on with the master plan. Give an outline.